A Phase II, Randomized, Placebo-Controlled, Multi-Center Study To Evaluate The Safety, Tolerability, Immunogenicity, And Antiretroviral Activity Of Dermavir (Lc002) Patch In Treatment-Na�ve HIV-1-Infected Patients

To evaluate the safety and tolerability of the DermaVir patch (LC002) in antiretroviral therapy na�ve adults infected with HIV-1. To establish a safe and well tolerated dosing regimen of the DermaVir patch (LC002) in antiretroviral therapy na�ve adults infected with HIV-1.